Rapport Therapeutics Inc
RAPP26.058USD
-0.882-3.27%
交易中 （美东）报价延迟15分钟
951.07M总市值
亏损市盈率 TTM
关于 Rapport Therapeutics Inc 公司
Rapport Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于发现和开发一系列精准小分子候选产品。该公司专注于开发一类新型精准神经药物，旨在为患者提供现有中枢神经系统疾病治疗方法的替代方案。该公司为患有中枢神经系统 (CNS) 疾病的患者推进了一系列治疗方案，包括局灶性癫痫、疼痛、躁郁症和听力障碍。该公司的离子型谷氨酸受体 (iGluR) 是由神经递质谷氨酸激活的配体门控离子通道。该公司的 RAP-219 是一种临床阶段的小分子，旨在通过选择性靶向一种称为 TARPy8 的 RAP 来实现神经解剖学特异性，TARPy8 与神经元 AMPAR 相关，后者是临床验证的癫痫靶点。
Rapport Therapeutics Inc简介
公司代码RAPP
公司名称Rapport Therapeutics Inc
上市日期Jun 07, 2024
CEOMr. Abraham N. (Abe) Ceesay
员工数量69
证券类型Ordinary Share
年结日Jun 07
公司地址99 High Street
城市BOSTON
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02110
电话18573218020
网址https://www.rapportrx.com/
公司代码RAPP
上市日期Jun 07, 2024
CEOMr. Abraham N. (Abe) Ceesay
Rapport Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
743.04K
-0.78%
Dr. Steven M. (Steve) Paul, M.D.
Dr. Steven M. (Steve) Paul, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
477.64K
--
Mr. David Bredt, M.D., Ph.D.
Mr. David Bredt, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
409.64K
-2.03%
Ms. Cheryl Gault
Ms. Cheryl Gault
Chief Operating Officer
Chief Operating Officer
171.93K
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Chief Financial Officer
Chief Financial Officer
10.00K
--
Dr. Ramiro (Raymond) Sanchez, M.D.
Dr. Ramiro (Raymond) Sanchez, M.D.
Independent Director
Independent Director
--
--
Dr. James I. Healey, M.D., Ph.D.
Dr. James I. Healey, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert J. (Rob) Perez
Mr. Robert J. (Rob) Perez
Independent Director
Independent Director
--
--
Ms. Wendy B. Young, Ph.D.
Ms. Wendy B. Young, Ph.D.
Independent Director
Independent Director
--
--
Mr. Reid Huber, Ph.D.
Mr. Reid Huber, Ph.D.
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
743.04K
-0.78%
Dr. Steven M. (Steve) Paul, M.D.
Dr. Steven M. (Steve) Paul, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
477.64K
--
Mr. David Bredt, M.D., Ph.D.
Mr. David Bredt, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
409.64K
-2.03%
Ms. Cheryl Gault
Ms. Cheryl Gault
Chief Operating Officer
Chief Operating Officer
171.93K
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Chief Financial Officer
Chief Financial Officer
10.00K
--
Dr. Ramiro (Raymond) Sanchez, M.D.
Dr. Ramiro (Raymond) Sanchez, M.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 9月29日 周一
更新时间: 9月29日 周一
持股股东
股东类型
持股股东
持股股东
占比
Third Rock Ventures, LLC
17.58%
Fidelity Management & Research Company LLC
11.87%
ARCH Venture Partners
8.09%
Capital World Investors
7.38%
Cormorant Asset Management, LP
6.38%
其他
48.71%
持股股东
持股股东
占比
Third Rock Ventures, LLC
17.58%
Fidelity Management & Research Company LLC
11.87%
ARCH Venture Partners
8.09%
Capital World Investors
7.38%
Cormorant Asset Management, LP
6.38%
其他
48.71%
股东类型
持股股东
占比
Investment Advisor
38.07%
Venture Capital
34.21%
Hedge Fund
8.83%
Investment Advisor/Hedge Fund
5.39%
Individual Investor
4.87%
Research Firm
2.81%
Bank and Trust
0.56%
Pension Fund
0.01%
Insurance Company
0.01%
其他
5.23%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
164
41.45M
89.90%
-333.41K
2025Q2
154
43.38M
118.86%
+3.70M
2025Q1
149
47.96M
131.36%
+9.87M
2024Q4
117
46.27M
126.51%
+9.23M
2024Q3
91
39.09M
106.87%
+12.18M
2024Q2
48
37.49M
102.49%
+37.49M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Third Rock Ventures, LLC
8.10M
17.58%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
5.47M
11.87%
-11.84K
-0.22%
Jun 30, 2025
ARCH Venture Partners
3.73M
8.09%
--
--
Jun 30, 2025
Capital World Investors
2.60M
5.64%
--
--
Jun 30, 2025
Cormorant Asset Management, LP
2.94M
6.38%
--
--
Jun 30, 2025
Capital International Investors
2.60M
5.64%
--
--
Jun 30, 2025
Sofinnova Investments, Inc
1.95M
4.22%
-48.02K
-2.41%
Sep 12, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.50M
5.42%
--
--
Jun 30, 2025
T. Rowe Price Associates, Inc.
1.50M
3.25%
+451.25K
+43.03%
Jun 30, 2025
Goldman Sachs & Company, Inc.
1.24M
2.68%
-9.28K
-0.75%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
1.92%
iShares Neuroscience and Healthcare ETF
0.92%
ALPS Medical Breakthroughs ETF
0.63%
Invesco Nasdaq Biotechnology ETF
0.11%
iShares Micro-Cap ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
Avantis US Small Cap Equity ETF
0.03%
ProShares Hedge Replication ETF
0.02%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比1.92%
iShares Neuroscience and Healthcare ETF
占比0.92%
ALPS Medical Breakthroughs ETF
占比0.63%
Invesco Nasdaq Biotechnology ETF
占比0.11%
iShares Micro-Cap ETF
占比0.11%
ProShares Ultra Nasdaq Biotechnology
占比0.11%
iShares Biotechnology ETF
占比0.05%
iShares Russell 2000 Value ETF
占比0.04%
Avantis US Small Cap Equity ETF
占比0.03%
ProShares Hedge Replication ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
